| Trial ID # | NCT00087087 |
| Phase | II |
| Drug Class | Chemotherapy |
| Drug Name | Pemetrexed |
| Alternate Drug Names | Pemetrexed disodium, Alimta |
| Drugs in Trial | Pemetrexed |
| Eligible Participant | Primary platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 51; median 4 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 21% (1CR, 9PR) |
| Clinically Significant Adverse Events | Serious AE: none |
| Conclusion | Favorable antitumor activity with mild and non-cumulative toxicity |
| Reference | Miller DS et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol (2009) 27(16):2686-91 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.